NICE issues ACD on bevacizumab for recurrent advanced platinum sensitive or partially platinum sensitive ovarian, fallopian tube, and primary peritoneal cancer
Source: NICE Area: News The National Institute for Health and Clinical Excellence (NICE) has issued for consultation an Appraisal Consultation Document (ACD) on the use of bevacizumab for treating advanced ovarian cancer that has returned six months or more after initial treatment with platinum-based chemotherapy (platinum-sensitive disease).   The following preliminary recommendations have been made:   . Bevacizumab in combination with gemcitabine and carboplatin is not recommended for treating the first recurrence of platinum-sensitive advanced ovarian cancer (including fallopian tube and primary ...
Source: NeLM - News - February 1, 2013 Category: Drugs & Pharmacology Source Type: news

NHS rationing body refuses drug for women with advanced ovarian cancer
Guidance from Nice says potential benefits of Avastin do not outweigh very high cost of drug, so cannot be recommendedWomen with advanced ovarian cancer will not receive the first life-extending drug in 15 years to treat the disease after the NHS rationing body said that its potential benefits did not outweigh its high cost.New draft guidance issued by the National Institute for Health and Clinical Excellence (Nice) means that Avastin will not be available on the NHS in cases where advanced ovarian cancer has returned at least six months after the woman has undergone platinum-based chemotherapy."In this instance the a...
Source: Guardian Unlimited Science - February 1, 2013 Category: Science Authors: Denis Campbell Tags: News Health guardian.co.uk Medical research Society Cancer UK news NHS Science Source Type: news

Cerulean Pharma to Present Avastin ®-CRLX101 Synergy Data
Cerulean Pharma Inc., a leader in designing and developing dynamically tumor-targeted nanopharmaceuticals, today announced that Scott D. Eliasof, Ph.D, vice president of research, will present data on Cerulean ’s most advanced experimental cancer treatment, CRLX101, at the 15th International Symposium on Anti-angiogenic Therapy. 01/30/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 30, 2013 Category: Urology & Nephrology Source Type: news

Combo Therapy Shines in Colon Cancer
SAN FRANCISCO (MedPage Today) -- First-line combination bevacizumab and capecitabine therapy may be an optimal first-line treatment for metastatic colorectal cancer in treatment-naive older patients, researchers reported here. (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - January 29, 2013 Category: Consumer Health News Source Type: news

Bevacizumab in mCRC: Mounting Evidence of BenefitBevacizumab in mCRC: Mounting Evidence of Benefit
Dr. Alok Khorana discusses a randomized trial indicating that bevacizumab added to standard chemotherapy after first progression in metastatic colorectal disease improves survival. Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 29, 2013 Category: Consumer Health News Tags: Hematology-Oncology Viewpoint Source Type: news

Elderly People With Advanced Bowel Cancer Do Just As Well As Younger People When Treated With Avastin® (Bevacizumab) With Chemotherapy
First randomized study prospectively evaluating Avastin in combination with chemotherapy specifically in elderly patients with advanced bowel cancer shows it can significantly stall disease more than chemotherapy alone Just a month after a leading charity warned that ageism in the NHS is stopping older cancer patients getting better treatments1 and the Health Secretary pledged to improve cancer treatment for those over 70,2 new data shows that elderly people with advanced bowel cancer, a disease which disproportionally affects older people, can benefit from treatment to th... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - January 29, 2013 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

FDA Approves Bevacizumab for Second-Line Combinations
Bevacizumab is now approved by the Food and Drug Administration for use in combination with fluoropyrimidine-irinotecan-based or fluoropyrimidine-oxaliplatin-based chemotherapy for metastatic colorectal... (Source: OncologySTAT Latest News)
Source: OncologySTAT Latest News - January 29, 2013 Category: Cancer & Oncology Source Type: news

Phase III data for pegfilgrastim (Neulasta®) in patients receiving chemotherapy for colorectal cancer
Source: BioSpace Area: News BioSpace has reported data from the double-blind, placebo-controlled PAVES study which is evaluating pegfilgrastim (Neulasta®) in patients receiving FOLFOX or FOLFIRI and bevacizumab for the first-line treatment of locally-advanced or metastatic colorectal cancer (n=845).   In the study, all patients received treatment with FOLFOX or FOLFIRI plus bevacizumab and they were randomised to one of two treatment arms that also received either placebo or 6mg of pegfilgrastim at least 24 hours after each cycle of chemotherapy. The primary endpoint was the incidence of grade 3 or 4 febrile...
Source: NeLM - News - January 29, 2013 Category: Drugs & Pharmacology Source Type: news

ASCO GI: Phase III Bevacizumab Results of the AVEX and TRIBE Trials
The same week that bevacizumab (Avastin) received a new indication for the treatment of metastatic colorectal cancer, results from two phase III trials involving the drug were presented at the American Society of Clinical Oncology 2013 Gastrointestinal Cancers Symposium (ASCO GI) held January 24–26 in San Francisco. (Source: Cancer Network)
Source: Cancer Network - January 28, 2013 Category: Cancer & Oncology Source Type: news

Roche's Avastin Approved For Colon Cancer Treatment By FDA
The U.S. Food and Drug Administration (FDA) has approved use of Roche's Avastin for patients with colorectal cancer that has gotten worse despite treatment with the medication. This new approval will permit patients who were already treated once with Avastin plus chemotherapy to be treated again with Avastin in combination with a different chemotherapy regimen. Hal Barron, MD, Roche's Chief Medical Officer and Head of Global Product Development said: "The majority of people diagnosed with metastatic colorectal cancer receive Avastin plus chemotherapy as their initial treatment... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - January 25, 2013 Category: Consumer Health News Tags: Colorectal Cancer Source Type: news

Avastin Wins FDA Approval For Colorectal Cancer Treatment
The U.S. Food and Drug Administration (FDA) has approved use of Roche's Avastin for patients with colorectal cancer that has gotten worse despite treatment with the medication. This new approval will permit patients who were already treated once with Avastin plus chemotherapy to be treated again with Avastin in combination with a different chemotherapy regimen. Hal Barron, MD, Roche's Chief Medical Officer and Head of Global Product Development said: "The majority of people diagnosed with metastatic colorectal cancer receive Avastin plus chemotherapy as their initial treatment... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - January 25, 2013 Category: Consumer Health News Tags: Colorectal Cancer Source Type: news

FDA approves use of bevacizumab for patients whose colorectal cancer has worsened despite previous treatment with the drug
Source: Reuters Area: News The FDA has approved the use of bevacizumab for patients whose colorectal cancer has worsened despite previous treatment with the drug. The new use will allow patients first treated with bevacizumab plus chemotherapy to be treated again with it in combination with a different chemotherapy regimen.   The clinical data to support this indication come from the phase 3 ML18147 study in 820 patients with unresectable metastatic colorectal cancer progressing up to 3 months after discontinuing first-line bevacizumab plus chemotherapy. They were randomised to second-line chemotherapy with (n= ...
Source: NeLM - News - January 25, 2013 Category: Drugs & Pharmacology Source Type: news

BMJ analysis: Optional copayments on anti-cancer drugs
Source: BMJ Area: News In this BMJ analysis, the authors note that "new cancer drugs are often expensive and offer low cost effectiveness, yet funders find it hard to resist the pressure to provide them to dying patients." They argue that because these drugs have only marginal efficacy it is reasonable to ask patients to contribute to their excess costs through optional copayments.   Their article covers the following topics:   . Example of bevacizumab and cetuximab . The regulatory game . General argument for copayments . Copayments and expensive cancer drugs . ...
Source: NeLM - News - January 25, 2013 Category: Drugs & Pharmacology Source Type: news

Avastin Wins New Colorectal Ca Indication
(MedPage Today) -- The FDA has approved a new use of bevacizumab (Avastin) as part of second-line combination therapy for metastatic colorectal cancer, the drug's manufacturer announced. (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - January 24, 2013 Category: Primary Care Source Type: news

Bevacizumab's Indication Extended in Colorectal CancerBevacizumab's Indication Extended in Colorectal Cancer
The use of the targeted agent after progression of the disease, already done in clinical practice, has now been approved and added to product labeling. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 24, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

FDA approves new use of Avastin plus chemotherapy for people with metastatic colorectal cancer
Roche today announced that the US Food and Drug Administration (FDA) has approved a new use of Avastin (bevacizumab) in combination with fluoropyrimidine-based irinotecan or oxaliplatin chemotherapy for people with metastatic colorectal cancer (mCRC). The new indication will allow people who received Avastin plus an irinotecan or oxaliplatin containing chemotherapy as an initial treatment (first-line) for mCRC to continue to receive Avastin plus a different irinotecan or oxaliplatin containing chemotherapy after their cancer worsens (second-line treatment). (Source: Roche Media News)
Source: Roche Media News - January 24, 2013 Category: Pharmaceuticals Source Type: news

FDA approves new use of Avastin plus chemotherapy for people with metastatic colorectal cancer
Roche today announced that the US Food and Drug Administration (FDA) has approved a new use of Avastin (bevacizumab) in combination with fluoropyrimidine-based irinotecan or oxaliplatin chemotherapy for people with metastatic colorectal cancer (mCRC). The new indication will allow people who received Avastin plus an irinotecan or oxaliplatin containing chemotherapy as an initial treatment (first-line) for mCRC to continue to receive Avastin plus a different irinotecan or oxaliplatin containing chemotherapy after their cancer worsens (second-line treatment). (Source: Roche Investor Update)
Source: Roche Investor Update - January 24, 2013 Category: Pharmaceuticals Source Type: news

FDA approves colon cancer drug combo
WASHINGTON, Jan. 23 (UPI) -- The U.S. Food and Drug Administration says it approved a new use of Avastin in combination with oxaliplatin chemotherapy for those colorectal cancer. (Source: Health News - UPI.com)
Source: Health News - UPI.com - January 24, 2013 Category: Consumer Health News Source Type: news

FDA approves new use for Roche's Avastin in colon cancer treatment
(Reuters) - The U.S. Food and Drug Administration on Wednesday approved the use of Roche's Avastin for patients whose colorectal cancer has worsened despite previous treatment with the drug. (Source: Reuters: Health)
Source: Reuters: Health - January 24, 2013 Category: Consumer Health News Tags: healthNews Source Type: news

Intravitreal Bevacizumab Injections for ROPIntravitreal Bevacizumab Injections for ROP
Are these promising findings sufficient to establish a new standard of treatment? Medscape Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 23, 2013 Category: Consumer Health News Tags: Ophthalmology Viewpoint Source Type: news

Bevacizumab QoL impact highlighted in ovarian cancer patients
The ICON7 study results suggest that improved progression-free survival with bevacizumab therapy for high-risk ovarian cancer may come at the cost of health-related quality of life. (Source: MedWire News - Ob/Gyn)
Source: MedWire News - Ob/Gyn - January 21, 2013 Category: OBGYN Source Type: news

Bevacizumab QoL impact highlighted in ovarian cancer patients
The ICON7 study results suggest that improved progression-free survival with bevacizumab therapy for high-risk ovarian cancer may come at the cost of health-related quality of life. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - January 21, 2013 Category: Cancer & Oncology Source Type: news

Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from ICON7 phase III trial
This study aims to describe the health-related quality-of-life (QoL) outcomes from ICON7.   ICON7 is a randomised, multicentre, open-label phase III trial in women with International Federation of Gynecology and Obstetrics (FIGO) high-risk stage I to IV epithelial ovarian cancer who had had surgery to debulk the tumour. They were randomised to receive either six cycles of standard chemotherapy (total 18 weeks) with carboplatin (AUC 5 or 6) and paclitaxel (175 mg/m2) alone (n= 764) or with bevacizumab (7.5 mg/kg) given intravenously with chemotherapy (n= 764) and ... (Source: NeLM - News)
Source: NeLM - News - January 18, 2013 Category: Drugs & Pharmacology Source Type: news

Avastin Misses Key Data Point in Brain Cancer Study
From Balochistan Times (Pakistan) (January 15, 2013) Swiss drugmaker Roche's cancer drug Avastin failed to make a statistically significant difference to survival rates of patients with a common form of brain cancer in a late-stage study,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 15, 2013 Category: Pharmaceuticals Source Type: news

Bevacizumab plus paclitaxel vs. bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: phase III TURANDOT trial interim results
Source: Lancet Oncology Area: News Randomised phase 3 trials in metastatic breast cancer have shown that combining bevacizumab with either paclitaxel or capecitabine improves progression-free survival (PFS) and response rate compared with chemotherapy alone but the relative efficacy of bevacizumab plus paclitaxel versus bevacizumab plus capecitabine has not been investigated. These two regimens were thus compared in an open-label, non-inferiority, phase III trial [TURANDOT (capeciTabine and bevacizumab Randomised Against avastiN anD taxOl Trial)].   The trial was designed to answer three main questions:   ...
Source: NeLM - News - January 10, 2013 Category: Drugs & Pharmacology Source Type: news

Oxaliplatin and bevacizumab disappoint for rectal cancer
The addition of bevacizumab and oxaliplatin to standard neoadjuvant chemoradiotherapy does not enhance clinical response rates in rectal cancer, show phase II study results. (Source: MedWire News - Gastroenterology)
Source: MedWire News - Gastroenterology - January 10, 2013 Category: Gastroenterology Source Type: news

Oxaliplatin and bevacizumab disappoint for rectal cancer
The addition of bevacizumab and oxaliplatin to standard neoadjuvant chemoradiotherapy does not enhance clinical response rates in rectal cancer, show phase II study results. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - January 10, 2013 Category: Cancer & Oncology Source Type: news

Bevacizumab/erlotinib combined therapy associated with substantial risk of esophageal toxicity
Socinski MA. J Clin Oncol. 2012:doi:10.1200/JXO.2012.43.1866. (Source: HemOncToday.com)
Source: HemOncToday.com - December 28, 2012 Category: Cancer & Oncology Source Type: news

Avastin and Lucentis are equivalent in treating age-related macular degeneration
At two years, Avastin (bevacizumab) and Lucentis (ranibizumab injection), two widely used drugs to treat age-related macular degeneration (AMD), improve vision when administered monthly or on an as needed basis, although greater improvements in vision were seen with monthly administration for this common, debilitating eye disease, according to researchers supported by the National Institutes of Health. (Source: News from NEI)
Source: News from NEI - April 30, 2012 Category: Opthalmology Tags: News and Events Source Type: news

Cancer patient denied Avastin in Wales
Kate Spall, who appears in this report, is a cancer advocate who has worked tirelessly on behalf of patients to assure they receive the treatments often denied them by government-run health care systems.  The drug mentioned here, Avastin®, is used in the USA to treat kidney cancer. 04/26/2012 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - April 26, 2012 Category: Urology & Nephrology Source Type: news

Cancer patient denied Avastin in Wales
Kate Spall, who appears in this report, is a cancer advocate who has worked tirelessly on behalf of patients to assure they receive the treatments often denied them by government-run health care systems.  The drug mentioned here, Avastin®, is used in the USA to treat kidney cancer.04/26/2012 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - April 26, 2012 Category: Urology & Nephrology Source Type: news

The use of unlicenced treatment for wet AMD
Reacting to news the Novartis is challenging the use of Avastin as an alternative to Lucentis for wet Age related Macular Degeneration Neal Patel, RPS spokesperson said: “Putting patients at the heart of decisions around therapy choice is what should drive NHS organisations and clin (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - April 24, 2012 Category: Drugs & Pharmacology Source Type: news

Position of the MPA regarding Lucentis and Avastin
Lucentis (ranibizumab) is approved for the treatment of neovascular age related macular degeneration (AMD), for the treatment of visual impairment due to diabetic macular oedema (DME) and retinal vein occlusions (RVO). (Source: MPA RSS news -)
Source: MPA RSS news - - March 16, 2012 Category: Medical Equipment Authors: Medical Products Agency, Sweden Source Type: news

Navigating Treatment Decisions
This article focuses on treatment for clear cell disease, but some of these treatments are also appropriate for patients with non-clear cell disease. Some patients may have only a single metastatic tumor that can be removed by surgery. But most patients with metastatic disease have tumors in many parts of the body. In order to treat all of these tumors, patients are given systemic therapies, which are drugs that travel through the bloodstream and can directly reach cells throughout the body. Immunotherapy is a type of treatment that gives a boost to the immune system. The goal of immunotherapy is to help the patient&rs...
Source: Kidney Cancer Association - February 7, 2012 Category: Urology & Nephrology Source Type: news

Navigating Treatment Decisions
This article focuses on treatment for clear cell disease, but some of these treatments are also appropriate for patients with non-clear cell disease. Some patients may have only a single metastatic tumor that can be removed by surgery. But most patients with metastatic disease have tumors in many parts of the body. In order to treat all of these tumors, patients are given systemic therapies, which are drugs that travel through the bloodstream and can directly reach cells throughout the body. Immunotherapy is a type of treatment that gives a boost to the immune system. The goal of immunotherapy is to help the patient&rsqu...
Source: Kidney Cancer Association - February 7, 2012 Category: Urology & Nephrology Source Type: news

Help Researchers and Earn $50.00
Researchers in the Department of Medical Social Sciences at Northwestern University, in a study paid for by AVEO Pharmaceuticals, are seeking individuals to participate in an online study of treatment side effects.  Participants must be at least 18 years old and have previously been diagnosed with kidney cancer.  Study participants do not need to be currently receiving treatment.  Participants will receive a $50.00 gift card for participating in the study.  More information about the study and links to enroll can be found here. Which of these three criteria do you meet? If you are currently recei...
Source: Kidney Cancer Association - December 16, 2011 Category: Urology & Nephrology Source Type: news

Help Researchers and Earn $50.00
Researchers in the Department of Medical Social Sciences at Northwestern University, in a study paid for by AVEO Pharmaceuticals, are seeking individuals to participate in an online study of treatment side effects. Participants must be at least 18 years old and have previously been diagnosed with kidney cancer.  Study participants donotneed to be currently receiving treatment.  Participants will receive a $50.00 gift card for participating in the study. More information about the study and links to enroll can be found here.Which of these three criteria do you meet? If you are currently receiving at le...
Source: Kidney Cancer Association - December 16, 2011 Category: Urology & Nephrology Source Type: news

Summary: International Kidney Cancer Symposium
Conclusions VHL/PBRM1 mutations confirmed 3rd subtype identified and under review but appears to be mis-classified tumors.  Shows value of molecular methods rather than new mechanistic insights. Integration with survival outcome—suggests molecular detailing can be prognostic Full integrative analysis in process Preliminary data can be found at http://tcga-data.nci.hih.gov/tcga/ FoxO Transcription Factors in mTORC1- Activated Renal Tumorigenesis:  Implications for the RCC Treatment Boyi Gan, MD Anderson Cancer Center FoxO Family Transcription Factors:  mammals possess FoxO...
Source: Kidney Cancer Association - December 15, 2011 Category: Urology & Nephrology Source Type: news

Summary: International Kidney Cancer Symposium
Conclusions VHL/PBRM1 mutations confirmed 3rd subtype identified and under review but appears to be mis-classified tumors.  Shows value of molecular methods rather than new mechanistic insights. Integration with survival outcome—suggests molecular detailing can be prognostic Full integrative analysis in process Preliminary data can be found athttp://tcga-data.nci.hih.gov/tcga/ FoxO Transcription Factors in mTORC1- Activated Renal Tumorigenesis:  Implications for the RCC Treatment Boyi Gan, MD Anderson Cancer Center FoxO Family Transcription Factors:  mammals possess FoxO1, FoxO3, FoxO4 an...
Source: Kidney Cancer Association - December 15, 2011 Category: Urology & Nephrology Source Type: news

NCCN Breast Cancer Panel Reaffirms Current Position and Recommendation Regarding the Use of Bevacizumab in Metastatic Breast Cancer
FORT WASHINGTON, PA - The Expert Breast Cancer Panel of the National Comprehensive Cancer Network® (NCCN®) met July 10-12, 2011 in Philadelphia, PA. At the meeting, the multidisciplinary breast cancer experts voted (24 For, 0 Against, 1 Abstain) in favor of maintaining the current position and recommendation in the NCCN Clinical Practice Guidelines in Onc... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - July 19, 2011 Category: Cancer & Oncology Source Type: news

NIH study finds Avastin and Lucentis are equally effective in treating age-related macular degeneration
Researchers are reporting results from the first year of a two-year clinical trial that Avastin, a drug approved to treat some cancers and that is commonly used off-label to treat age-related macular degeneration (AMD), is as effective as the Food and Drug Administration-approved drug Lucentis for the treatment of AMD. (Source: News from NEI)
Source: News from NEI - April 28, 2011 Category: Opthalmology Tags: News and Events Source Type: news

FDA Revokes Avastin Approval
Read more . . .12/17/2010 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 17, 2010 Category: Urology & Nephrology Source Type: news

NCCN Guidelines for Breast Cancer Updated; Bevacizumab Recommendation Affirmed
The National Comprehensive Cancer Network® (NCCN®) recently updated the NCCN Guidelines™ for Breast Cancer to address the use of bevacizumab in metastatic disease. October 18, 2010 FORT WASHINGTON, PA - The National Comprehensive Cancer Network® (NCCN®) recently updated the NCCN Clinical Practice Guidelines for Oncology (NCCN Guidelines™) for Breast Cancer to affirm the recommendation regarding the use of bevacizumab (Avastin®, Genentech/Roche) in the treatment of metastatic breast cancer.... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - October 18, 2010 Category: Cancer & Oncology Source Type: news

Patient reported side effects from molecularly targeted therapies in renal cell carcinoma
Conclusions: These results suggest that the patient-reported impact of molecularly targeted agent side effects may be more significant than suggested by phase III clinical trials. These results also identify specific side effects towards which improved symptom management strategies and enhanced patient education can be directed. Better side effect management may increase treatment duration and improve clinical outcomes. 06/25/2010 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - June 25, 2010 Category: Urology & Nephrology Source Type: news

Patient reported side effects from molecularly targeted therapies in renal cell carcinoma
Conclusions:These results suggest that the patient-reported impact of molecularly targeted agent side effects may be more significant than suggested by phase III clinical trials. These results also identify specific side effects towards which improved symptom management strategies and enhanced patient education can be directed. Better side effect management may increase treatment duration and improve clinical outcomes.06/25/2010 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - June 25, 2010 Category: Urology & Nephrology Source Type: news

Notes from the Eigth International Kidney Cancer Symposium
We are grateful to patient advocate Katherine Phillion for sharing her notes from our fall kidney cancer meeting.  Eigth International Kidney Cancer Symposium September 2009     Management of Small Renal Masses and Localized Renal Carcinoma Case Presentation and Background Robert G. Uzzo, M.D., FACS There are a lot of options available to manage small (
Source: Kidney Cancer Association - January 25, 2010 Category: Urology & Nephrology Source Type: news

Notes from the Eigth International Kidney Cancer Symposium
We are grateful to patient advocate Katherine Phillion for sharing her notes from our fall kidney cancer meeting. Eigth International Kidney Cancer SymposiumSeptember 2009  Management of Small Renal Masses and Localized Renal CarcinomaCase Presentation and BackgroundRobert G. Uzzo, M.D., FACSThere are a lot of options available to manage small (
Source: Kidney Cancer Association - January 25, 2010 Category: Urology & Nephrology Source Type: news